{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:48:35Z","timestamp":1791856115682,"version":"4.3.4"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jconrel.2022.03.057","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T11:22:08Z","timestamp":1648812128000},"page":"798-810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Non-oral routes, novel formulations and devices of contraceptives: An update"],"prefix":"10.1016","volume":"345","author":[{"given":"Deepak Ramazor","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Wairkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.03.057_bb0005","first-page":"e1152","article-title":"Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990\u20132019, lancet","volume":"8","author":"Bearak","year":"2020","journal-title":"Glob. Health"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.contraception.2007.04.006","article-title":"Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents","volume":"76","author":"Han","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0015","series-title":"Medical Eligibility Criteria for Contraceptive Use","first-page":"1","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0020","series-title":"Contracept. Technol. 19th Revis. Ed.","first-page":"19","article-title":"Choosing a contraceptive: efficacy, safety, and personal considerations","author":"Trussell","year":"2007"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.contraception.2018.12.001","article-title":"Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women","volume":"99","author":"Heffron","year":"2019","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0030","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0035","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.transproceed.2007.09.014","article-title":"Oral and transdermal hormonal contraception in women after kidney transplantation","volume":"39","author":"Pietrzak","year":"2007","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpdd.185","article-title":"Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study","volume":"4","author":"Zurth","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1054\/cuog.2003.0304","article-title":"Non-oral hormonal contraception","author":"Gupt","year":"2003","journal-title":"Curr. Obstet. Gynaecol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0050","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1359-6446(05)03499-9","article-title":"Delivery options for contraceptives","volume":"10","author":"Sitruk-Ware","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/13697130400012239","article-title":"Transdermal hormone therapy: gels and patches","volume":"7","author":"Samsioe","year":"2004","journal-title":"Climacteric"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0060","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/01.AOG.0000161958.70059.db","article-title":"Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist","volume":"105","author":"Potts","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0065","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/01.AOG.0000160430.61799.f6","article-title":"Extended use of transdermal norelgestromin\/ethinyl estradiol: a randomized trial","volume":"105","author":"Stewart","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2020.11.011","article-title":"Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: phase 3 clinical trial results","volume":"103","author":"Nelson","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0075","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/archderm.1995.01690210094016","article-title":"Contraceptive efficacy","volume":"131","author":"Trussell","year":"1995","journal-title":"Arc Dermatol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0080","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.contraception.2011.03.005","article-title":"Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats","volume":"84","author":"Agrawal","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0085","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s12325-019-01108-z","article-title":"Adhesion evaluation of AG200-15: an investigational transdermal contraceptive delivery system","volume":"36","author":"Ocheltree","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/AOG.0000000000000095","article-title":"Low-dose levonorgestrel and ethinyl estradiol patch and pill a randomized controlled trial","volume":"123","author":"Kaunitz","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0095","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2009.05.017","article-title":"Double-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol","volume":"377","author":"Gao","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/WHE.13.71","article-title":"Effects of an ethinyl estradiol\/gestodene transdermal contraceptive patch on the endometrium: a single-center, uncontrolled study","volume":"10","author":"Merz","year":"2014","journal-title":"Women Health"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.contraception.2019.12.012","article-title":"Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: a double-blind, randomized, bioequivalence and adhesion study in healthy women","volume":"101","author":"Parasrampuria","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2012.12.014","article-title":"Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies","volume":"441","author":"Sachdeva","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0115","article-title":"Prausnitz, sustained release of a contraceptive","author":"Li","year":"2012","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0120","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2021.08.012","article-title":"Immediate detachment of microneedles by interfacial fracture for sustained delivery of a contraceptive hormone in the skin","volume":"337","author":"Lee","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0125","series-title":"Silk Fibroin Microneedle Patches for the Sustained Release of Levonorgestrel","first-page":"0","author":"Yavuz","year":"2020"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0130","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijpharm.2017.10.035","article-title":"Novel dissolving microneedles for enhanced transdermal delivery of levonorgestrel: in vitro and in vivo characterization","volume":"534","author":"Yao","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0135","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2019.03.011","article-title":"Pharmaceutical jewelry: earring patch for transdermal delivery of contraceptive hormone","volume":"301","author":"Mofidfar","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.contraception.2010.07.008","article-title":"Vaginal ring contraception","volume":"83","author":"Kerns","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0145","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003088-200039030-00005","article-title":"Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring","volume":"39","author":"Timmer","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0150","first-page":"2","article-title":"The vaginal contraceptive pill","volume":"19","author":"Coutinho","year":"1985","journal-title":"IPPF Med. Bull."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0010-7824(02)00514-0","article-title":"The combined contraceptive vaginal ring, NuvaRing\u00ae: an international study of user acceptability","volume":"67","author":"Nov\u00e1k","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.contraception.2006.03.022","article-title":"Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives","volume":"74","author":"Sabatini","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0165","first-page":"1","article-title":"Comparative in vitro study on the local tolerance and efficacy of benzalkonium chloride, myristalkonium chloride and nonoxynol-9 as active principles in vaginal contraceptives","volume":"0","author":"Alfaiate","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0170","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11095-005-2490-1","article-title":"Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent","volume":"22","author":"Garg","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0175","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1773-2247(14)50130-X","article-title":"Development and in vitro evaluation of a novel contraceptive vaginal mucoadhesive propranolol hydrochloride film","volume":"24","author":"Borumand","year":"2014","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1371\/journal.pone.0067365","article-title":"Designed chemical intervention with thiols for prophylactic contraception","volume":"8","author":"Sharma","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0010-7824(97)00097-8","article-title":"A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9 postcoital testing and colposcopy","volume":"56","author":"Mauck","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0190","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107832118","article-title":"Hexavalent sperm-binding IgG antibody released from vaginal film for development of potent on-demand nonhormonal female contraception","volume":"118","author":"Shrestha","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0015-0282(00)01636-8","article-title":"Contraceptive efficacy and safety studies of a novel microemulsion-based lipophilic vaginal spermicide","volume":"75","author":"D\u2019Cruz","year":"2001","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0200","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.contraception.2012.09.012","article-title":"Effectiveness of an optimized benzalkonium chloride gel as vaginal contraceptive: a randomized controlled trial among Chinese women","volume":"87","author":"Li","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.contraception.2011.04.013","article-title":"Contraceptive efficacy and safety of HerbOshieldTM vaginal gel in rats","volume":"85","author":"Singh","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0210","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1095\/biolreprod.102.014043","article-title":"Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device","volume":"69","author":"Haineault","year":"2003","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0215","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejps.2014.09.019","article-title":"(Copper-curcumin) \u03b2-cyclodextrin vaginal gel: delivering a novel metal-herbal approach for the development of topical contraception prophylaxis","volume":"65","author":"Gaurav","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005347","article-title":"Copper containing intra-uterine devices for contraception","author":"Kulier","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.bpobgyn.2014.05.004","article-title":"The intrauterine device and the intrauterine system","volume":"28","author":"Stephen Searle","year":"2014","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0230","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/13625187.2013.853034","article-title":"A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system","volume":"19","author":"Weisberg","year":"2014","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0235","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.whi.2018.06.003","article-title":"The impact of sexual satisfaction, functioning, and perceived contraceptive effects on sex life on IUD and implant continuation at 1 year","volume":"28","author":"Sanders","year":"2018","journal-title":"Womens Health Issues"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0240","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1471-0528.2010.02652.x","article-title":"Copper T380A intrauterine device for emergency contraception: A prospective, multicentre, cohort clinical trial","volume":"117","author":"Wu","year":"2010","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0245","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.contraception.2015.08.014","article-title":"Controlled release of copper from an intrauterine device using a biodegradable polymer","volume":"92","author":"Ramakrishnan","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0250","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.contraception.2015.01.011","article-title":"Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for intrauterine devices","volume":"91","author":"Heinemann","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0255","first-page":"587","article-title":"Trends in oral contraceptive and intrauterine device use among reproductive-aged women in the US from 1999 to 2017","volume":"32","author":"King","year":"2021","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12905-022-01611-6","article-title":"Reasons for low utilization of intrauterine device utilisation amongst short term contraceptive users in Hossana town, Southern Ethiopia: a qualitative study","volume":"22","author":"Woldeyohannes","year":"2022","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0265","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/17455057.2.2.191","article-title":"Subcutaneous versus intramuscular depot methoxyprogesterone acetate: a comparative review","volume":"2","author":"Simon","year":"2006","journal-title":"Women Health"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0270","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.contraception.2004.06.011","article-title":"Contraceptive efficacy and safety of DMPA-SC","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0275","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.contraception.2013.07.002","article-title":"Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm","volume":"89","author":"Halpern","year":"2014","journal-title":"Contraceptio."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0280","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.contraception.2014.01.022","article-title":"Observational study of the acceptability of Sayana\u00ae Press among intramuscular DMPA users in Uganda and Senegal","volume":"89","author":"Burke","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0285","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.contraception.2004.06.011","article-title":"Contraceptive efficacy and safety of DMPA-SC","volume":"70","author":"Jain","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0290","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2004.11.013","article-title":"Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg\/0.65 ml) contraceptive formulation in asian women","volume":"26","author":"Cheng Toh","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0295","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.contraception.2011.03.014","article-title":"Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg)","volume":"84","author":"Sierra-Ram\u00edrez","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.steroids.2018.07.010","article-title":"Esters of levonorgestrel and etonogestrel intended as single, subcutaneous-injection, long-lasting contraceptives","volume":"137","author":"Meece","year":"2018","journal-title":"Steroids"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2020.11.008","article-title":"Clinically established biodegradable long acting injectables: an industry perspective","volume":"167","author":"Nkanga","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0310","article-title":"Subcutaneous or intramuscular? Confronting a parenteral administration dilemma","volume":"14","author":"Prettyman","year":"2005","journal-title":"Medsurg Nurs."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1365.002","article-title":"Contraception today","volume":"1092","author":"Benagiano","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/app.46068","article-title":"Biodegradable polymeric injectable implants for long-term delivery of contraceptive drugs","volume":"135","author":"Manoukian","year":"2018","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0325","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.contraception.2012.11.010","article-title":"Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics","volume":"87","author":"Thurman","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0330","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.eclinm.2021.100800","article-title":"Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: findings from a randomised, multicentre, open-label trial","volume":"34","author":"Beksinska","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0335","doi-asserted-by":"crossref","first-page":"100026","DOI":"10.1016\/j.conx.2020.100026","article-title":"Comparison of pregnancy incidence among African women in a randomized trial of intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUDs) or a levonorgestrel (LNG) implant for contraception","volume":"2","author":"Onono","year":"2020","journal-title":"Contracept. X"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0340","doi-asserted-by":"crossref","first-page":"111159","DOI":"10.1016\/j.msec.2020.111159","article-title":"Synthesis and characterization of PCL-DA:PEG-DA based polymeric blends grafted with SMA hydrogel as bio-degradable intrauterine contraceptive implant","volume":"116","author":"Subramanian","year":"2020","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0345","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jconrel.2020.12.044","article-title":"Advances in controlled release hormonal technologies for contraception: A review of existing devices, underlying mechanisms, and future directions","volume":"330","author":"Sivasankaran","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0350","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0015-0282(16)58689-0","article-title":"Contraceptive efficacy, pharmacokinetics, and safety of Annuelle\u00ae biodegradable norethindrone pellet implants","volume":"66","author":"Raymond","year":"1996","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0355","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijgo.2005.06.007","article-title":"Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant","volume":"90","author":"Otero Flores","year":"2005","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0360","doi-asserted-by":"crossref","first-page":"110.e1","DOI":"10.1016\/j.ajog.2012.05.002","article-title":"Pharmacokinetics of the etonogestrel contraceptive implant in obese women","volume":"207","author":"Mornar","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0365","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s13224-011-0066-z","article-title":"Implanon: subdermal single rod contraceptive implant","volume":"61","author":"Bhatia","year":"2011","journal-title":"J. Obstet. Gynecol. India"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0370","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijgo.2010.01.018","article-title":"Bone mineral density in women using the subdermal contraceptive implant Implanon for at least 2 years","volume":"109","author":"Pongsatha","year":"2010","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0375","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/AOG.0b013e31820ce2f0","article-title":"Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant","volume":"117","author":"Espey","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0380","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ijgo.13744","article-title":"Trends in subdermal contraceptive implant use in Mexico 2009\u20132018: a population-based study","volume":"156","author":"Darney","year":"2022","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0385","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003088-198917050-00001","article-title":"Intranasal drug delivery: potential advantages and limitations from a clinical pharmacokinetic perspective","volume":"17","author":"Pontiroli","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0390","series-title":"Indian Journal of Pharmaceutical Sciences Scienti fi c Publication of the Indian Pharmaceutical Association Recent Trends in Drug-Likeness Prediction : A Comprehensive Aqua Triggered In Situ Gelling Microemulsion for Nasal Delivery","first-page":"2007","volume":"69","author":"Med","year":"2007"},{"key":"10.1016\/j.jconrel.2022.03.057_bb0395","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.fertnstert.2003.10.015","article-title":"Nasal delivery of levonorgestrel for contraception: an experimental study in rats","volume":"81","author":"Shahiwala","year":"2004","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0400","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1211\/jpp.58.1.0003","article-title":"Preliminary investigation of the nasal delivery of liposomal leuprorelin acetate for contraception in rats\u2020","volume":"58","author":"Shahiwala","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.03.057_bb0405","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/10717540600740102","article-title":"Pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route","volume":"14","author":"Ding","year":"2007","journal-title":"Drug Deliv."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922001912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922001912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:34:38Z","timestamp":1759163678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922001912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":81,"alternative-id":["S0168365922001912"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.057","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-oral routes, novel formulations and devices of contraceptives: An update","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}